Novocure 2025 Q3 Earnings Revenue Beats Estimates as Losses Widen

Novocure (NASDAQ: NVCR) reported Q3 2025 results on October 31, 2025, with revenue exceeding estimates but net losses widening. The stock surged 7% pre-market after the earnings beat, though profitability challenges persist. Management outlined a path to profitability by 2027, emphasizing four cancer indications by year-end 2026.

Revenue

, . The increase was driven by active patient growth in glioblastoma (GBM) therapy, , . International expansion in Germany, Japan, and France also contributed to the top-line performance.

Earnings/Net Income

, , , , in the prior-year period. . Despite the revenue beat, . , .

Post-Earnings Price Action Review

, . However, the 30-day post-earnings period (October 30–November 29, 2025) saw mixed performance due to limited data availability beyond October 31. Short-term volatility remains a risk, . Holding the stock for 30 days post-earnings suggests moderate upside potential, .

CEO Commentary

Executive Chairman emphasized Novocure’s transition to a platform therapy company, targeting four cancer indications by year-end 2026. He acknowledged challenges in the non-small cell lung cancer (NSCLC) launch, citing poor patient health and competition from targeted therapies. CEO highlighted progress in pancreatic cancer (PANOVA-3 data submitted to the FDA) and brain metastases (METIS PMA filing expected by year-end 2025). CFO reiterated confidence in achieving adjusted EBITDA breakeven by 2027 at $700–750 million in revenue.

Guidance

Management outlined a disciplined approach to profitability, leveraging existing infrastructure for upcoming launches in pancreatic cancer and brain metastases. The company expects to submit a PMA application for brain metastases in Q4 2025 and awaits NCCN guideline updates for NSCLC. Adjusted EBITDA breakeven is targeted for 2027, with revenue contributions from new indications.

Additional News

1. , signaling confidence in long-term growth.

2. Institutional Investor Shifts, .

3. Analyst Ratings, . The stock maintains a “Hold” consensus rating, .

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1761970210451.jpg.png" style="max-width:100%;">

Backtest Results

, 2025, but the 30-day holding period (October 30–November 29) lacks full data. Key risks include short-term volatility (e.g., . For moderate-risk investors, the strategy aligns with short-term goals but requires close monitoring of regulatory updates and commercialization progress.

Risks & Considerations

- Profitability.

- Debt.

- Regulatory Uncertainty.

- Market Volatility.

Conclusion

Novocure’s Q3 2025 results highlight revenue growth driven by patient expansion and international reach but underscore profitability challenges. While the stock reacted positively to the revenue beat, long-term success hinges on regulatory approvals, NSCLC commercialization, and disciplined cost management. Investors should weigh short-term momentum against structural risks before committing.